Davies, Sperling Share 2015 Potamkin Prize
In a Solomonic move, a prestigious prize for research in neurodegenerative disease goes to a veteran tauist and a self-professed inhabitant of “amyloid land.”
6397 RESULTS
Sort By:
In a Solomonic move, a prestigious prize for research in neurodegenerative disease goes to a veteran tauist and a self-professed inhabitant of “amyloid land.”
A protein instigates axon degeneration by promoting destruction of the essential enzyme cofactor, NAD+.
As DIAN Plans Trial Number Two, the Goal Is to Go Big DIAN-TU Pharma Consortium NexGen Trial Meeting
Researchers identify N-terminally extended Aβ peptides that are toxic to synapses and rise after BACE1 inhibition, though whether they occur in human disease remains unclear.
Researchers report the highest resolution structure to date for γ-secretase, the multisubunit complex that churns out Aβ.
Several different striatal markers may help researchers track early deterioration in Huntington's and Parkinson’s diseases.
Davies, Sperling Share 2015 Potamkin Prize New PET Tracer Tracks Preclinical Movement Disorders Neurodegenerative Proteins in the Skin Could be Diagnostic The 67th American Academy of Neurology conference drew more than 12,000 attendees to Washington, D.C
Knockout mice lived to old age with mild brain abnormalities but no sign of motor neuron disease.
A discontinued β-secretase blocker reportedly quieted inflammation and cleared amyloid plaques by way of microglial activation.
A stem cell model suggests the β-secretase-generated C-terminal fragment of the amyloid precursor protein raises tau protein levels.
Aβ42 molecules assume an S-shaped configuration within fibrils. The structure varies markedly from that adopted by Aβ40.
Scientists find neurodegenerative proteins squirreled away in the skin cells of patients. Could this present an untapped source of biomarkers?
A revised plan of action for AD research has emerged from the Alzheimer’s Disease Research Summit 2015.
Repeated activation of the perforant pathway over five months doubled the area of amyloid plaques in transgenic mice.
Denali Therapeutics gets off the ground with one of the largest Series A rounds ever.